EP on EP Episode 95: Malignant Mitral Valve Prolapse Syndrome (Part 1)

Introduction

In this section, Dr. Sam Ashubatham is introduced as an electrophysiologist of the Mayo Clinic and the topic of discussion, malignant mitral valve prolapse syndrome, is introduced.

Introducing Dr. Sam Ashubatham

• Dr. Sam Ashubatham is introduced as an academic and practicing electrophysiologist of the Mayo Clinic.

• The host mentions that Dr. Ashubatham prefers to be called "electrophysiologist of the Mayo Clinic."

Defining Malignant Mitral Valve Prolapse Syndrome

• Malignant mitral valve prolapse syndrome is defined as a diagnosis characterized by complex ventricular ectopy, abnormal repolarization, and bay leaflet prolapse.

• Mitral annular disjunction is identified as a key feature of malignant mitral valve prolapse syndrome.

• Polymorphic non-sustained VT and abnormal late catalanium enhancement are additional features that have been brought to light in recent years.

Mitral Annular Disjunction

In this section, Dr. Ashubatham discusses mitral annular disjunction and its role in malignant mitral valve prolapse syndrome.

Understanding Mitral Annular Disjunction

• Mitral annular disjunction occurs when the mitral valve is inserted on the atrium instead of being inserted right on the annulus.

• This gives rise to some abnormal type tissue that's ventricular to the point of attachment of this annulus.

• It's usually part of a tetrad with other features like bay leaflet prolapse, complex ventricular ectopy, and abnormal repolarization.

Changes in Diagnosis Over Time

In this section, Dr. Ashubatham discusses changes in the diagnosis of malignant mitral valve prolapse syndrome over time.

Changes in Diagnosis

• The extent of regurgitation is not a key feature of malignant mitral valve prolapse syndrome.

• Buy leaflet prolapse large floppy valves probably play a role in the actor pages from contact just hitting against the outflow track back and the annulus on the papillary muscles.

• Mitral annular disjunction is now recognized as a key feature of malignant mitral valve prolapse syndrome.

Mitral Valve Prolapse and Sudden Cardiac Death

In this section, the speaker discusses the relationship between mitral valve prolapse (MVP) and sudden cardiac death. They explain how MVP can be a risk factor for cardiac arrest and arrhythmias.

MVP Anatomy and Risk Factors

• Patients with only MVP have suffered from cardiac arrest.

• The tissue that gives rise to arrhythmias is a continuum of atrial tissue.

• Mitral annular disjunction is an important risk factor for patients with prolapse.

Screening for Sudden Death Risk

• Patients with worrisome symptoms, arrhythmia, or morphology should be screened.

• Holter monitoring or stress tests can detect complex ectopy in patients with palpitations.

• Patients who have malignant-looking polymorphic VT need careful counseling about the syndrome and may require defibrillators or MRI scans.

Treatment Options for Mitral Valve Prolapse

In this section, the speaker discusses treatment options for mitral valve prolapse. They explain how treatment depends on the severity of the condition and whether it has caused any complications.

Treating Mild MVP

• Most patients with mild MVP do not require treatment.

• Lifestyle changes such as avoiding caffeine or alcohol may help reduce symptoms.

Treating Severe MVP

• Surgery may be necessary if there is severe regurgitation or if other complications arise.

• Repairing or replacing the mitral valve can improve symptoms and prevent further damage to the heart.

Screening for Cardiac Abnormalities

In this section, the speakers discuss the use of deep downward T waves as an initial screening test for cardiac abnormalities.

Use of Deep Downward T Waves as a Screening Test

• Deep downward T waves are used by one speaker as an initial screening test for cardiac abnormalities.

• The other speaker finds it interesting that a normal T wave could indicate low risk and has not paid attention to it from that angle.

Conclusion and Next Steps

In this section, the speakers conclude their discussion on screening for cardiac abnormalities and plan to regroup in part two to discuss therapy.

Conclusion and Regrouping

• The speakers conclude their discussion on screening for cardiac abnormalities.

• They plan to regroup in part two to discuss therapy.